What is FRONTEO’s AI?
November 20, 2023
Examples of implementing AI in Drug Discovery by stage
November 20, 2023
New Drug Development Status & News from Pharmaceutical Companies Manufacturers
Here provides a summary of news of interest to the pharmaceutical industry, including the status of new drug development by pharmaceutical companies and manufacturers.
Summary of New Drug Development News in May 2023
1. Summary of New Drug Development News in May 2023
AnGes applies for progeria treatment drug in-licensed from U.S. company Eiger
1.1 AnGes applies for progeria treatment drug in-licensed from U.S. company Eiger
On May 12, AnGes announced that it has filed an application with the Ministry of Health, Labour and Welfare for a domestic manufacturing and marketing approval for Zokinvi (generic name, lonafarnib), a treatment for Hutchinson-Gilford progeria syndrome and progeroid laminopathy, which is an infant premature aging syndrome.
It was approved in the U.S. in 2020, and AnGes signed an agreement for exclusive distribution in Japan last May. The number of patients expected to use the drug in Japan is expected to be several.
Astellas acquired for a record price! What is the potential of the new ophthalmology drug candidate “ACP”?
1.2 Astellas acquired for a record price! What is the potential of the new ophthalmology drug candidate “ACP”?
On May 1, Astellas Pharma Inc. announced the acquisition of Iberic Bio, a U.S. biopharmaceutical company developing new drugs for the ophthalmologic field.
Through this acquisition, Astellas expects to strengthen its ophthalmology business by acquiring Iberic Bio's technology, development know-how, and sales platform, including ACP, a new drug candidate for ""age-related macular degeneration"".
Until now, Astellas has focused on the development and marketing of anticancer drugs and menopause drug candidates, but with the acquisition, Astellas aims to expand revenues and corporate growth with ""ACP"" as its third pillar.
JCR Pharma and Angelini Pharma
Collaborate on epilepsy drug development and commercialization
1.3 JCR Pharma and Angelini Pharma
Collaborate on epilepsy drug development and commercialization
On May 11, JCR Pharma announced a collaboration with Italy's Angelini Pharma for the development and commercialization of biologic therapies for epilepsy.
The collaboration is expected to combine JCR Pharma's extensive expertise in biotechnology and Angelini's expertise in neurological diseases to jointly develop therapeutic drugs.
Angelini received an option right to an exclusive license to commercialize the drug outside Japan, while JCR received R&D and sales milestones, as well as royalties on sales.
Development of Kidney Drug Bardoxolone Methyl Discontinued
1.4 Development of Kidney Drug Bardoxolone Methyl Discontinued
On May 10, Kyowa Kirin announced the discontinuation of the development of bardoxolone methyl, which has been under development for diabetic kidney disease and other conditions.
This is because clinical trials did not show results in suppressing the onset of ESRD (end-stage renal disease).
In conjunction with this, the application for domestic manufacturing and sales approval for Alport syndrome, which was filed in July 2021, was also withdrawn, and development for this indication was also discontinued.
About BB-1701, an antibody-drug conjugate
Eisai Signs Co-Development Agreement with BlissBio
1.5 About BB-1701, an antibody-drug conjugate
Eisai Signs Co-Development Agreement with BlissBio
On May 8, Eisai announced that it has entered into a co-development agreement with Bliss Biopharmaceutical of China for BB-1701, an antibody-drug conjugate (ADC) with option rights.
Under the agreement, Eisai will pay an upfront payment and development milestone to BlissBio and conduct a P2 study in breast cancer. Eisai will receive option rights for development and commercialization outside of China, Hong Kong, Macau and Taiwan.
Development Pipeline Information Summary
2. Development Pipeline Information Summary
A development pipeline is a new drug candidate in the preliminary stages of being marketed as pharmaceuticals. It is said that the future prospects of a pharmaceutical company depends on how promising the pipeline is.
This page provides information on the development pipelines of pharmaceutical companies as of May 12, 2023 (to be updated as needed). Please check it out.
